logo-loader
viewFSD Pharma

FSD Pharma kicks off in-human study of micro-PEA in Australia

The drug targets receptors in the endocannabinoid system and is designed to treat symptoms associated with conditions such as fibromyalgia

Australia on a map
The study is meant to evaluate the safety, tolerability and pharmacokinetics of the drug in healthy volunteers

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) has begun a Phase 1 human study of its anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA) after winning approval from the Ethics Committee of the Alfred Hospital in Victoria, Australia. 

The drug works by targeting receptors in patients’ endocannabinoid system and is designed to treat the symptoms associated with conditions such as fibromyalgia. The new Phase 1 study is meant to evaluate the safety, tolerability and pharmacokinetics of the drug in healthy volunteers.

"The initiation of this Phase 1 in-human safety and tolerability clinical study of ultra-micronized formulation of PEA is a ground-breaking milestone for our company as we stride forward to find novel anti-inflammatory treatment outcomes for patients by targeting the CB2 receptors of the endocannabinoid system," CEO Raza Bokhari said in a statement.

READ: FSD Pharma Inc generates $7.7M in proceeds through sale of interest in Cannara Biotech

Bokhari gave credit to the head of the company’s BioSciences division.

"I must congratulate Dr. Edward Brennan, President of FSD Pharma’s BioSciences Division, and his very qualified team on delivering this milestone on schedule,” Bokhari said. “Dr. Brennan's decades of experience in drug development is very noteworthy, and I share his confidence that this Phase 1 in-human study based on US FDA-approved guidelines will produce favorable data. 

“The study would validate considerable scientific literature already published, over the years, in the European Union, that claims safety and tolerability of micro-PEA, which is being dispensed in Italy and Spain as a prescription-based medical food supplement since 2004.”

FSD Pharma is focused on the research and development of cannabinoid-based treatments for several central nervous system disorders, including fibromyalgia, and irritable bowel syndrome.

Headquartered at the former Kraft plant in Cobourg, Ontario, with large expansion potential, FSD also grows medical-grade cannabis at its 25,000 square foot facility in Ontario.

Through its wholly-owned subsidiary FV Pharma Inc, the group is a licensed producer under Canada's Cannabis Act, having received its cultivation license in October 2017 and its sale for medical purposes license in April 2019.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: FSD Pharma

Price: 5.01 CAD

CSE:HUGE
Market: CSE
Market Cap: $51.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

FSD Pharma raises more than C$10M in private placement, makes progress with...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive how the firm is planning to use its recently-raised C$10.125 million. Bokhari says the Cobourg, Ontario-headquartered company had struck agreements with institutional investors for the purchase and sale of 1.5 million of...

3 weeks, 3 days ago

2 min read